XXXX of the scalp and face: the Mayo Clinic experience.

@entity1 @entity2695 @entity5 @entity5426 @entity1349
IMPORTANCE: The etiology and optimal treatment are unknown for @entity5426 , an aggressive @entity5 that affects vascular endothelial cells and can be mistaken for benign lesions such as @entity2695 . OBJECTIVE: To determine the treatment outcomes of @entity1 with @entity5426 of the face or scalp treated with a combination of surgery, radiation therapy, and/or chemotherapy. DESIGN, SETTING, AND @entity1 : Retrospective study of 55 @entity1 with @entity5426 of the face or scalp treated between January 1, 1973, and December 31, 2012, at a tertiary-care academic medical institution. INTERVENTIONS: Surgery, radiation therapy, and/or chemotherapy. MAIN OUTCOMES AND MEASURES: Locoregional control (LRC), @entity1349 ( @entity1349 ), and @entity1349 ( @entity1349 ). RESULTS: Fifty-five @entity1 had @entity5426 localized to the face or scalp. Forty of these @entity1 (73%) received a combination of surgery, radiation therapy, and/or chemotherapy. Eight @entity1 (15%) were treated with surgery alone, 1 (2%) with radiation alone, 5 (9%) with chemotherapy alone, and 1 (2%) with observation alone. Median (range) follow-up for surviving @entity1 was 25.2 (4.7-227.1) months. Five-year LRC, @entity1349 , and @entity1349 (95% CI) were 18% (7%-32%), 16% (6%-31%), and 38% (21%-54%), respectively. Of 36 @entity1 with failed treatment, 34 had failure in a local and/or regional site. On univariate analysis, the use of multimodality therapy (vs no multimodality therapy) was associated with higher 5-year LRC (95% CI) (20% [3%-37%] vs 11% [0%-29%]; P   =   .04), higher @entity1349 (19% [2%-36%] vs 10% [0%-27%]; P   =   .02), and higher @entity1349 (46% [26%-66%] vs 16% [0%-43%]; P   =   .04). Age 70 years or older (vs <70 years) was associated with lower 5-year LRC (95% CI) (5% [0%-14%] vs 48% [23%-74%]; P   =   .02) and lower @entity1349 (5% [0%-13%] vs 49% [24%-75%]; P   =   .04). Radiation therapy (vs no radiation therapy) was associated with higher 5-year LRC (95% CI) (20% [3%-36%] vs 12% [0%-32%]; P   =   .02) and higher @entity1349 (19% [2%-35%] vs 12% [0%-31%]; P   =   .004). On multivariable analysis, age younger than 70 years (vs >= 70 years) was associated with improved 5-year LRC (95% CI) (48% [23%-74%] vs 5% [0%-14%]; P   =   .03) and @entity1349 (49% [24%-75%] vs 49% [24%-75%]; P   =   .04). CONCLUSIONS AND RELEVANCE: Multimodality therapy for @entity5426 is associated with improved LRC, @entity1349 , and @entity1349 . Younger @entity1 with resectable disease undergoing multimodality therapy for @entity5426 had the best clinical outcomes.
